Industry News
NeuroSearch halts Alzheimer's drug plan
Danish biotech firm NeuroSearch has decided not to start clinical development of drugs aimed at treating Alzheimer's disease. [ + ]
C3 raises $10m
Perth-based Clinical Cell Culture (C3, ASX:CCE) has placed 28.6 million new fully paid ordinary shares worth AUD$10 million with Australian institutional and sophisticated investors. [ + ]
Bioinformatics peak body committee elected
Bioinformatics Australia, Australia's peak body for bioinformatics, hosted by industry organisation AusBiotech, has announced its newly elected committee. [ + ]
Aussies asked to apply for UK biotech trade mission
A trade mission to World Life Sciences Week being held in London this October is taking applications from Australian biotech companies. [ + ]
Cervical cancer vaccine pioneer wins leadership prize
Prof Ian Frazer, whose research on a vaccine for a leading cause of cervical cancer is being developed by CSL and Merck & Co, has won the inaugural 2005 CSIRO Eureka Prize for Leadership in Science. [ + ]
NZ's AgVax acquired by Dutch firm Intervet
New Zealand-based animal vaccine specialist AgVax Developments has been taken over by Intervet, a business unit of Dutch healthcare giant Akzo Nobel. [ + ]
EvoGenix lists at 20 per cent premium
Antibody therapeutic developer EvoGenix (ASX:EGX) listed today on the Australian Stock Exchange at AUD$0.30, 20 per cent above its issue price of AUD$0.25. [ + ]
Select Vaccines out-licenses hepatitis A diagnostic test
Select Vaccines (ASX:SLT) has licensed the manufacture, global marketing and distribution of its rapid hepatitis A diagnostic technology to US-based Rapid Medical Diagnostic (RMD), but has kept the distribution rights for the test in Australia and New Zealand. [ + ]
Avexa ends year with two years' cash in the bank
Melbourne-based biotech Avexa (ASX:AVX) has finished its first financial year of operation with AUD$15.7 million in the bank -- enough operating cash for two years, according to CEO Julian Chick . [ + ]
Apollo claims competitive advantage
Recently listed Sydney biopharma Apollo Life Sciences (ASX:AOP) has claimed that its human-expressed vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels, performs five times better in an international proliferation test than a leading competitor's protein and the World Health Organisation's (WHO) protein standard. [ + ]
Detecting links between banknotes and drugs
Research published in the journal Rapid Communications in Mass Spectrometry is the description of a method that can detect a pattern of contamination on banknotes from drug-related crime that is different from the pattern seen in general circulation. The process is claimed to be significantly faster than other previous methods.
[ + ]Qld team on the pulse of migraine genetics
What causes those headaches that keep on thumping after you've exceeded your recommended daily allowance of garden-variety analgesics? A team at QIMR is close to finding out. [ + ]
Prima to gain full ownership of its four subsidiaries
Prima Biomed (ASX:PRR) and the Austin Research Institute (ARI) have reached an in principle agreement enabling Prima to gain full ownership of its four subsidiary companies, Oncomab, Panvax, Cancer Vac and Arthron. [ + ]
Progen to collaborate with Sanofi-Aventis on prostate cancer trials
Brisbane cancer drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) will expand its phase II clinical trial program into prostate cancer to assess the efficacy and safety of its PI-88 angiogenesis inhibitor in combination with Sanofi-Aventis' chemotherapy agent Taxotere (docetaxel). [ + ]
Bottom-line boost for LCT
A week after revealing spectacular preclinical results from its novel NeurotropinCell therapy for Huntington's disease, Auckland-based cell-therapy specialist Living Cell Technologies (ASX:LCT) has announced a therapeutic injection in its bottom line, after a successful capital raising pumped AUD$2.3 million into its coffers. [ + ]
